BioTech

BUZZ-U.S. STOCKS ON THE MOVE-Uber, Yelp, Nektar

Credit: REUTERS/SHANNON STAPLETON

A compilation of the most active stocks on U.S. exchanges. For faster updates on individual market-movers, Eikon users please use search string "STXBZ US" and Thomson One users please search "RT/STXBZ US".

Eikon search string for individual stock moves: STXBZ

The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi

The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh

U.S. stocks futures slipped on Friday, a day after Wall Street roared back to record its biggest one-day rise in two months, as investors grappled with fresh trade tensions and political turmoil in Britain and Italy. .N

At 7:06 ET, Dow e-minis 1YMc1 were down 0.54% at 26,222. S&P 500 e-minis ESc1 were down 0.63% at 2,921.5, while Nasdaq 100 e-minis NQc1 were down 0.86% at 7,669. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Callaway Golf Co ELY.N, up 10.5% ** Turquoise Hill Resources Ltd TRQ.N, up 6.5% ** Yelp Inc YELP.N, up 5.9% The top three NYSE percentage losers premarket .PRPL.NQ: ** Farfetch Ltd FTCH.N, down 37% ** ProPetro Holding Corp PUMP.N, down 30.9% ** Fastly Inc FSLY.N, down 23.6% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Arcadia Biosciences Inc RKDA.O, up 29.9% ** Guardion Health Sciences Inc GHSI.O, up 23.4% ** Genius Brands International Inc GNUS.O, up 21.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Viewray Inc VRAY.O, down 46.6% ** Nektar Therapeutics NKTR.O, down 30.6% ** Waitr Holdings Inc WTRH.O, down 21.5% ** Uber UBER.N: down 6.8% premarket ** Lyft Inc LYFT.O: down 1.5% premarket BUZZ-Tumbles on Q2 revenue miss

** Nektar NKTR.O: down 30.6% premarket BUZZ-Sinks as management discloses manufacturing discrepancies in cancer drug ** Lexicon Pharma LXRX.O: up 12.5% premarket BUZZ-Gains on positive data for diabetes drug ** ViewRay VRAY.O: down 46.6% premarket BUZZ-Set to hit 2-1/2 year low after slashing rev forecast ** WPP Plc WPP.N: up 5.5% premarket BUZZ-Jumps as new client wins lift Q2 trading ** Amarin's AMRN.O: down 20.6% premarket BUZZ-Slump after delayed drug review is a buying opportunity - Jefferies

(Compiled by by Arunima Kumar in Bengaluru)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More